Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Evaluation of the effectiveness and security profile of vedolizumab in inflammatory bowel disease
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-E-009-Monday
- By: GARCIA SACRISTAN, Ana Andrea (Virgen de la salud Hospital, PHARMACY, toledo, Spain)
- Co-author(s): Ana Andrea Garcia Sacristan: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Marta Fdz Arévalo: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Cristina Blazquez: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Helena Quirós: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Manuel Martinez Sesmero: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Javier Manzano: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Ana Domiguez: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
Paloma Moya: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain - Abstract:
Backgrounds
Vedolizumab(VD)is a monoclonal antibody-IgG1 indicated in treatment of inflammatory bowel disease(IBD),including ulcerative colitis(UC)and Chron Desease(CD),who has failed other therapies.Pharmacists and Disgestive specialists have worked together to implement a protocol for the correct use of VD
Aims
To evaluate effectiveness and safety
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023